secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-10-01T12:00:17+00:00
Accession:  0001213900-26-105457
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Allarity cites patent awards, CLIA lab certification to advance stenoparib DRP companion diagnostic
--------------------------------------------------------------------------------

- Allarity says recent patent awards plus CLIA certification of its in-house lab let it retain sole control of the stenoparib-DRP test as a companion diagnostic.
- Stenoparib-DRP comprises a 414-gene expression signature including genes tied to WNT pathway activity; DRP tests have been developed for dozens of cancer therapies.
- At AACR 2026, an exploratory analysis of a prior Phase 2 cohort of advanced ovarian cancer patients on twice-daily stenoparib linked higher pretreatment DRP scores to longer overall survival.
- CEO Thomas Jensen said the DRP-survival association helps inform the path toward FDA approval; stenoparib remains the principal development focus.
- No financial results, patient counts, partnership terms or pivotal-trial timeline were disclosed in the update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/0001213900-26-105457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026105457/ea0307298-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-105457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer